<code id='AEA0711F41'></code><style id='AEA0711F41'></style>
    • <acronym id='AEA0711F41'></acronym>
      <center id='AEA0711F41'><center id='AEA0711F41'><tfoot id='AEA0711F41'></tfoot></center><abbr id='AEA0711F41'><dir id='AEA0711F41'><tfoot id='AEA0711F41'></tfoot><noframes id='AEA0711F41'>

    • <optgroup id='AEA0711F41'><strike id='AEA0711F41'><sup id='AEA0711F41'></sup></strike><code id='AEA0711F41'></code></optgroup>
        1. <b id='AEA0711F41'><label id='AEA0711F41'><select id='AEA0711F41'><dt id='AEA0711F41'><span id='AEA0711F41'></span></dt></select></label></b><u id='AEA0711F41'></u>
          <i id='AEA0711F41'><strike id='AEA0711F41'><tt id='AEA0711F41'><pre id='AEA0711F41'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:knowledge    Page View:3
          Pascal Soriot - Senate Finance Committee
          AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

          LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

          Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga. 

          advertisement

          “We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Kristina Burow of ARCH Venture Partners shares her next big bets STAT
          Kristina Burow of ARCH Venture Partners shares her next big bets STAT

          AlexHogan/STATKristinaBurowhasawell-trainedeye.That’strueofherworkatARCHVenturePartners,oneofthedrug

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          An inside look at PIPEs, biotech's buzzy new financing tool

          MollyFerguson/STATBiotechisawashinPIPEs.Thenumbersbehindtheseprivatelynegotiatedpurchasesofpublic-co